

Global Dermatological Drugs Market Report and Forecast 2024-2032

Market Report (7 days) | 2024-02-07 | 160 pages | EMR Inc.

AVAILABLE LICENSES:

- Single User License \$5499.00
- Five User License \$7499.00
- Corporate License \$9499.00

Report description:

Global Dermatological Drugs Market Report and Forecast 2024-2032

Global Dermatological Drugs Market Outlook

The global dermatological drugs market size was valued at USD 22.59 billion in 2023, driven by increasing shift towards biologics and targeted therapies across the globe. The market size is anticipated to grow at a CAGR of 11.3% during the forecast period of 2024-2032 to achieve a value of USD 59.2 billion by 2032.

Dermatological Drugs: Introduction

Dermatological drugs are medications specifically formulated to treat skin conditions and diseases. They encompass a wide range of products, including topical creams, ointments, gels, and systemic medications like oral pills and injectables. These drugs are used to treat various conditions such as acne, dermatitis, psoriasis, skin infections, and skin cancer. The choice of medication depends on the specific condition, its severity, and the patient's overall health, aiming to relieve symptoms, improve skin appearance, and prevent complications.

Key Trends in the Global Dermatological Drugs Market

There's a significant shift towards biologics and targeted therapies, particularly for chronic conditions like psoriasis and atopic dermatitis. These treatments focus on specific pathways or cells involved in the disease process, offering more efficacy and fewer side effects compared to traditional therapies.

Personalized or precision medicine approaches are becoming more prevalent, where treatments are tailored to individual patient characteristics, genetic makeup, or specific biomarkers.

Advances in formulation technology are improving the efficacy and patient compliance of topical treatments. Innovations include better drug delivery systems that enhance penetration of active ingredients and controlled-release mechanisms.

There's a growing market for cosmetic dermatological products, driven by an increasing emphasis on appearance and anti-aging. This includes treatments for wrinkles, pigmentation disorders, and hair loss.

Telemedicine and digital health apps are gaining traction for diagnosing and managing skin conditions. These technologies offer greater accessibility to dermatological care, particularly in underserved areas or during situations like the COVID-19 pandemic.

Research in regenerative medicine and stem cells is opening up new possibilities for treating skin conditions. This includes therapies for wound healing, scar reduction, and potentially even reversing hair loss.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

The global increase in skin conditions, partly due to aging populations and environmental factors, is driving demand for dermatological treatments.

Despite the growth, companies in the dermatological drug market face challenges related to regulatory hurdles, pricing pressures, and reimbursement issues, impacting market dynamics and access to new treatments.

Global Dermatological Drugs Market Segmentation

Market Breakup by Diseases

- Acne
- Dermatitis
- Psoriasis
- Skin Cancer
- Rosacea
- Alopecia
- Others

Market Breakup by Type

- Prescription-based Drugs
- Over-the-Counter Drugs

Market Breakup by Route of Administration

- Topical Administration
- Oral Administration
- Parenteral Administration
- Others

Market Breakup by End User

- Hospitals
- Homecare

Market Breakup by Region

- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa

Global Dermatological Drugs Market Overview

In North America, the dermatological drugs market is advanced and dynamic, driven by a high focus on aesthetic appearance and quality of life. The region sees significant research and development activities, leading to the introduction of innovative treatments, including biologics for conditions like psoriasis and atopic dermatitis. Consumer awareness about skin health is high, fueling the demand for both prescription and over-the-counter skincare products. Regulatory support for rapid approval of breakthrough therapies also contributes to market dynamics.

Europe's market is characterized by stringent regulatory standards ensuring the safety and efficacy of dermatological drugs. There's a strong focus on research, with numerous initiatives aimed at understanding skin diseases at a molecular level and developing targeted treatments. Public healthcare systems in many European countries provide broad access to dermatological care, supporting market growth. The market is also influenced by a growing demand for cosmetic and anti-aging products alongside treatments for serious skin conditions.

The market in the Asia-Pacific region is rapidly expanding, driven by increasing consumer income, changing lifestyles, and a growing emphasis on personal appearance. The region has a high demand for skincare products, including those for acne, pigmentation disorders, and anti-aging. Cultural factors and climatic conditions also influence the prevalence of certain skin conditions, shaping market trends. However, the market is diverse, with variations in healthcare access and regulatory landscapes across different countries.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Global Dermatological Drugs Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players.

- [] AbbVie Inc. (Allergan PLC)
- [] Amgen Inc.
- [] Galderma
- [] GlaxoSmithKline Plc.
- [] Leo Pharma
- [] Johnson & Johnson
- [] Novartis AG
- [] Organon International (Merck & Co. Inc.)
- [] Pfizer Inc.
- [] Sun Pharmaceutical Industries Limited
- [] Sanofi
- [] Bausch Health Companies Inc
- [] Bristol-Myers Squibb Company
- [] F. Hoffmann-La Roche Ltd
- [] AstraZeneca

We at Expert Market Research always strive to provide you with the latest information. The numbers in the article are only indicative and may be different from the actual report.

Table of Contents:

- 1 Preface
 - 1.1 Objectives of the Study
 - 1.2 Key Assumptions
 - 1.3 Report Coverage - Key Segmentation and Scope
 - 1.4 Research Methodology
- 2 Executive Summary
- 3 Global Dermatological Drugs Market Overview
 - 3.1 Global Dermatological Drugs Market Historical Value (2017-2023)
 - 3.2 Global Dermatological Drugs Market Forecast Value (2024-2032)
- 4 Global Dermatological Drugs Market Landscape
 - 4.1 Global Dermatological Drugs Developers Landscape
 - 4.1.1 Analysis by Year of Establishment
 - 4.1.2 Analysis by Company Size
 - 4.1.3 Analysis by Region
 - 4.2 Global Dermatological Drugs Product Landscape
 - 4.2.1 Analysis by Type
 - 4.2.2 Analysis by Indication
 - 4.2.3 Analysis by Route of Administration
- 5 Global Dermatological Drugs Market Dynamics
 - 5.1 Market Drivers and Constraints
 - 5.2 SWOT Analysis
 - 5.3 Porter's Five Forces Model

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 5.4 Key Demand Indicators
- 5.5 Key Price Indicators
- 5.6 Industry Events, Initiatives, and Trends
- 5.7 Value Chain Analysis
- 6 Global Dermatological Drugs Market Segmentation
 - 6.1 Global Dermatological Drugs Market by Diseases
 - 6.1.1 Market Overview
 - 6.1.2 Acne
 - 6.1.3 Dermatitis
 - 6.1.4 Psoriasis
 - 6.1.5 Skin Cancer
 - 6.1.6 Rosacea
 - 6.1.7 Alopecia
 - 6.1.8 Others
 - 6.2 Global Dermatological Drugs Market by Type
 - 6.2.1 Market Overview
 - 6.2.2 Prescription-based Drugs
 - 6.2.3 Over-the-Counter Drugs
 - 6.3 Global Dermatological Drugs Market by Route of Administration
 - 6.3.1 Market Overview
 - 6.3.2 Topical Administration
 - 6.3.3 Oral Administration
 - 6.3.4 Parenteral Administration
 - 6.3.5 Others
 - 6.4 Global Dermatological Drugs Market by End User
 - 6.4.1 Market Overview
 - 6.4.2 Hospitals
 - 6.4.3 Homecare
 - 6.5 Global Dermatological Drugs Market by Region
 - 6.5.1 Market Overview
 - 6.5.2 North America
 - 6.5.3 Europe
 - 6.5.4 Asia Pacific
 - 6.5.5 Latin America
 - 6.5.6 Middle East and Africa
- 7 North America Dermatological Drugs Market
 - 7.1 Market Share by Country
 - 7.2 United States of America
 - 7.3 Canada
- 8 Europe Dermatological Drugs Market
 - 8.1 Market Share by Country
 - 8.2 United Kingdom
 - 8.3 Germany
 - 8.4 France
 - 8.5 Italy
 - 8.6 Others
- 9 Asia Pacific Dermatological Drugs Market

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 9.1 Market Share by Country
- 9.2 China
- 9.3 Japan
- 9.4 India
- 9.5 ASEAN
- 9.6 Australia
- 9.7 Others
- 10 Latin America Dermatological Drugs Market
 - 10.1 Market Share by Country
 - 10.2 Brazil
 - 10.3 Argentina
 - 10.4 Mexico
 - 10.5 Others
- 11 Middle East and Africa Dermatological Drugs Market
 - 11.1 Market Share by Country
 - 11.2 Saudi Arabia
 - 11.3 United Arab Emirates
 - 11.4 Nigeria
 - 11.5 South Africa
 - 11.6 Others
- 12 Patent Analysis
 - 12.1 Analysis by Type of Patent
 - 12.2 Analysis by Publication year
 - 12.3 Analysis by Issuing Authority
 - 12.4 Analysis by Patent Age
 - 12.5 Analysis by CPC Analysis
 - 12.6 Analysis by Patent Valuation
 - 12.7 Analysis by Key Players
- 13 Grants Analysis
 - 13.1 Analysis by year
 - 13.2 Analysis by Amount Awarded
 - 13.3 Analysis by Issuing Authority
 - 13.4 Analysis by Grant Application
 - 13.5 Analysis by Funding Institute
 - 13.6 Analysis by NIH Departments
 - 13.7 Analysis by Recipient Organization
- 14 Clinical Trials Analysis
 - 14.1 Analysis by Trial Registration Year
 - 14.2 Analysis by Trial Status
 - 14.3 Analysis by Trial Phase
 - 14.4 Analysis by Therapeutic Area
 - 14.5 Analysis by Geography
- 15 Funding Analysis
 - 15.1 Analysis by Funding Instances
 - 15.2 Analysis by Type of Funding
 - 15.3 Analysis by Funding Amount
 - 15.4 Analysis by Leading Players

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 15.5 Analysis by Leading Investors
- 15.6 Analysis by Geography
- 16 Partnership and Collaborations Analysis
 - 16.1 Analysis by Partnership Instances
 - 16.2 Analysis by Type of Partnership
 - 16.3 Analysis by Leading Players
 - 16.4 Analysis by Geography
- 17 Supplier Landscape
 - 17.1 AbbVie Inc. (Allergan PLC).
 - 17.1.1 Financial Analysis
 - 17.1.2 Product Portfolio
 - 17.1.3 Demographic Reach and Achievements
 - 17.1.4 Mergers and Acquisition
 - 17.1.5 Certifications
 - 17.2 Amgen Inc.
 - 17.2.1 Financial Analysis
 - 17.2.2 Product Portfolio
 - 17.2.3 Demographic Reach and Achievements
 - 17.2.4 Mergers and Acquisition
 - 17.2.5 Certifications
 - 17.3 Galderma
 - 17.3.1 Financial Analysis
 - 17.3.2 Product Portfolio
 - 17.3.3 Demographic Reach and Achievements
 - 17.3.4 Mergers and Acquisition
 - 17.3.5 Certifications
 - 17.4 GlaxoSmithKline Plc.
 - 17.4.1 Financial Analysis
 - 17.4.2 Product Portfolio
 - 17.4.3 Demographic Reach and Achievements
 - 17.4.4 Mergers and Acquisition
 - 17.4.5 Certifications
 - 17.5 Leo Pharma
 - 17.5.1 Financial Analysis
 - 17.5.2 Product Portfolio
 - 17.5.3 Demographic Reach and Achievements
 - 17.5.4 Mergers and Acquisition
 - 17.5.5 Certifications
 - 17.6 Johnson & Johnson
 - 17.6.1 Financial Analysis
 - 17.6.2 Product Portfolio
 - 17.6.3 Demographic Reach and Achievements
 - 17.6.4 Mergers and Acquisition
 - 17.6.5 Certifications
 - 17.7 Novartis AG
 - 17.7.1 Financial Analysis
 - 17.7.2 Product Portfolio

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 17.7.3 Demographic Reach and Achievements
- 17.7.4 Mergers and Acquisition
- 17.7.5 Certifications
- 17.8 Organon International (Merck & Co. Inc.)
 - 17.8.1 Financial Analysis
 - 17.8.2 Product Portfolio
 - 17.8.3 Demographic Reach and Achievements
 - 17.8.4 Mergers and Acquisition
 - 17.8.5 Certifications
- 17.9 Pfizer Inc.
 - 17.9.1 Financial Analysis
 - 17.9.2 Product Portfolio
 - 17.9.3 Demographic Reach and Achievements
 - 17.9.4 Mergers and Acquisition
 - 17.9.5 Certifications
- 17.10 Sun Pharmaceutical Industries Limited
 - 17.10.1 Financial Analysis
 - 17.10.1 Product Portfolio
 - 17.10.2 Demographic Reach and Achievements
 - 17.10.3 Mergers and Acquisition
 - 17.10.4 Certifications
- 17.11 Sanofi
 - 17.11.1 Financial Analysis
 - 17.11.2 Product Portfolio
 - 17.11.3 Demographic Reach and Achievements
 - 17.11.4 Mergers and Acquisition
 - 17.11.5 Certifications
- 17.12 Bausch Health Companies Inc
 - 17.12.1 Financial Analysis
 - 17.12.2 Product Portfolio
 - 17.12.3 Demographic Reach and Achievements
 - 17.12.4 Mergers and Acquisition
 - 17.12.5 Certifications
- 17.13 Bristol-Myers Squibb Company
 - 17.13.1 Financial Analysis
 - 17.13.2 Product Portfolio
 - 17.13.3 Demographic Reach and Achievements
 - 17.13.4 Mergers and Acquisition
 - 17.13.5 Certifications
- 17.14 F. Hoffmann-La Roche Ltd
 - 17.14.1 Financial Analysis
 - 17.14.2 Product Portfolio
 - 17.14.3 Demographic Reach and Achievements
 - 17.14.4 Mergers and Acquisition
 - 17.14.5 Certifications
- 17.15 AstraZeneca
 - 17.15.1 Financial Analysis

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 17.15.2 Product Portfolio
- 17.15.3 Demographic Reach and Achievements
- 17.15.4 Mergers and Acquisition
- 17.15.5 Certifications
- 18 Global Dermatological Drugs Market - Distribution Model (Additional Insight)
 - 18.1 Overview
 - 18.2 Potential Distributors
 - 18.3 Key Parameters for Distribution Partner Assessment
- 19 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 20 Company Competitiveness Analysis (Additional Insight)
 - 20.1 Very Small Companies
 - 20.2 Small Companies
 - 20.3 Mid-Sized Companies
 - 20.4 Large Companies
 - 20.5 Very Large Companies
- 21 Payment Methods (Additional Insight)
 - 21.1 Government Funded
 - 21.2 Private Insurance
 - 21.3 Out-of-Pocket

*Additional insights provided are customisable as per client requirements.

Global Dermatological Drugs Market Report and Forecast 2024-2032

Market Report (7 days) | 2024-02-07 | 160 pages | EMR Inc.

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$5499.00
	Five User License	\$7499.00
	Corporate License	\$9499.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

☐ ** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2025-05-05"/>
		Signature	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com